{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:59:47Z","timestamp":1791050387925,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jgar.2024.11.011","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T14:28:35Z","timestamp":1732804115000},"page":"15-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pharmacokinetic\/pharmacodynamic analysis of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults by Monte Carlo simulation"],"prefix":"10.1016","volume":"40","author":[{"given":"Xiao-Chen","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Feng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Rong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.11.011_bib0001","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14740338.2018.1446939","article-title":"Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections","volume":"17","author":"Hardalo","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jgar.2024.11.011_bib0002","doi-asserted-by":"crossref","first-page":"dlac088","DOI":"10.1093\/jacamr\/dlac088","article-title":"Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme","volume":"4","author":"Carvalhaes","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.11.011_bib0003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijid.2021.04.014","article-title":"Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019)","volume":"107","author":"Carvalhaes","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2024.11.011_bib0004","doi-asserted-by":"crossref","first-page":"18033","DOI":"10.1038\/nrdp.2018.33","article-title":"Methicillin-resistant Staphylococcus aureus","volume":"4","author":"Lee","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jgar.2024.11.011_bib0005","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/cid\/cit617","article-title":"Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary","volume":"58","author":"O'Riordan","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.11.011_bib0006","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/cid\/cit618","article-title":"Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary","volume":"58","author":"Das","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.11.011_bib0007","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/INF.0000000000003010","article-title":"Safety and efficacy of oral and\/or intravenous tedizolid phosphate from a randomized phase 3 trial in adolescents with acute bacterial skin and skin structure infections","volume":"40","author":"Bradley","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2024.11.011_bib0008","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/cid\/cit614","article-title":"Methicillin-resistant Staphylococcus aureus therapy: past, present, and future","volume":"58","author":"Rodvold","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.11.011_bib0009","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jac\/dkv302","article-title":"Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid","volume":"71","author":"Barber","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0010","article-title":"Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2024.11.011_bib0011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jgar.2015.04.003","article-title":"Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013)","volume":"3","author":"Sader","year":"2015","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.11.011_bib0012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12941-023-00574-2","article-title":"Phenotypic and genotypic characterization of linezolid resistance and the effect of antibiotic combinations on methicillin-resistant Staphylococcus aureus clinical isolates","volume":"22","author":"AbdAlhafiz","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2024.11.011_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00284-023-03579-4","article-title":"Population analysis of daptomycin-non-susceptible methicillin-resistant Staphylococcus aureus reveals the presence of variants that contribute to daptomycin resistance","volume":"81","author":"Kanesaka","year":"2024","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.jgar.2024.11.011_bib0014","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1128\/AAC.00859-08","article-title":"In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains","volume":"52","author":"Shaw","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0015","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1128\/AAC.01565-10","article-title":"In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model","volume":"55","author":"Louie","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0016","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1128\/AAC.00881-16","article-title":"Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014","volume":"60","author":"Pfaller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0017","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/AAC.00076-10","article-title":"Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections","volume":"55","author":"Prokocimer","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0018","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jac\/dkr403","article-title":"In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci","volume":"67","author":"Rodr\u00edguez-Avial","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0019","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1080\/1120009X.2024.2339706","article-title":"Evaluating omadacycline dosing regimens against drug-resistant pathogens including Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in adults: a pharmacokinetic\/pharmacodynamic analysis using Monte Carlo simulation","volume":"36","author":"Wei","year":"2024","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40262-021-01099-7","article-title":"Pharmacokinetics and pharmacodynamics of tedizolid","volume":"61","author":"Iqbal","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2024.11.011_bib0021","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1128\/AAC.05354-11","article-title":"Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers","volume":"56","author":"Housman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0022","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijid.2021.04.014","article-title":"Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019)","volume":"107","author":"Carvalhaes","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2024.11.011_bib0023","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/INF.0000000000003030","article-title":"Pharmacokinetics and safety of single-dose tedizolid phosphate in children 2 to <12 years of age","volume":"40","author":"Arrieta","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2024.11.011_bib0024","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.pcl.2017.08.005","article-title":"New antimicrobial agents for the treatment of Staphylococcal infections in children","volume":"64","author":"Sharma","year":"2017","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.jgar.2024.11.011_bib0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/INF.0000000000003597","article-title":"Activity of tedizolid and comparator agents against Gram-positive isolates causing skin and skin structure infections in pediatric patients in United States hospitals (2015-2019)","volume":"41","author":"Carvalhaes","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2024.11.011_bib0026","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1089\/sur.2023.055","article-title":"Pharmacokinetic and pharmacodynamic considerations of novel antibiotic agents for pediatric infections: a narrative review","volume":"24","author":"Shafiekhani","year":"2023","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.jgar.2024.11.011_bib0027","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/ph13110333","article-title":"New antibiotics for the treatment of acute bacterial skin and soft tissue infections in pediatrics","volume":"13","author":"Principi","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jgar.2024.11.011_bib0028","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1128\/AAC.00502-11","article-title":"Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0029","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11095-022-03425-5","article-title":"Differences in pharmacokinetic\/pharmacodynamic parameters of tedizolid against VRE and MRSA","volume":"40","author":"Liu","year":"2023","journal-title":"Pharm Res"},{"key":"10.1016\/j.jgar.2024.11.011_bib0030","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/phar.1458","article-title":"Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2024.11.011_bib0031","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/phar.1337","article-title":"Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2024.11.011_bib0032","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bjid.2015.12.007","article-title":"Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections","volume":"20","author":"Ortiz-Covarrubias","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jgar.2024.11.011_bib0033","first-page":"255","article-title":"Activity of linezolid and tedizolid against clinical isolates of methicillin-resistant and methicillin and linezolid resistant Staphylococcus aureus: an in vitro comparison","volume":"29","author":"Pe\u00f1uelas","year":"2016","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.jgar.2024.11.011_bib0034","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-017-0601-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of oxazolidinones","volume":"57","author":"Roger","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2024.11.011_bib0035","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/phar.1491","article-title":"Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance","volume":"34","author":"Rybak","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2024.11.011_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106112","article-title":"Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic\/pharmacodynamic analysis using Monte Carlo simulation","volume":"56","author":"Wei","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.11.011_bib0037","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/dkh511","article-title":"The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe","volume":"55","author":"Masterton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0038","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1248\/bpb.b22-00276","article-title":"Target therapeutic ranges of anti-MRSA drugs, linezolid, tedizolid and daptomycin, and the necessity of TDM","volume":"45","author":"Matsumoto","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jgar.2024.11.011_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01282-23","article-title":"Safety and tolerability of tedizolid as oral treatment for bone and joint infections","volume":"11","author":"Miller","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2024.11.011_bib0040","doi-asserted-by":"crossref","first-page":"ofac028","DOI":"10.1093\/ofid\/ofac028","article-title":"Real-world use of tedizolid phosphate for 28 days or more: a case series describing tolerability and clinical success","volume":"9","author":"Morrisette","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2024.11.011_bib0041","doi-asserted-by":"crossref","first-page":"22","DOI":"10.37201\/req\/s01.06.2021","article-title":"Tedizolid: new data and experiences for clinical practice","volume":"34","author":"Salavert Llet\u00ed","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.jgar.2024.11.011_bib0042","doi-asserted-by":"crossref","first-page":"e710","DOI":"10.1093\/cid\/ciab032","article-title":"A phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated Gram-positive hospital-acquired or ventilator-associated bacterial pneumonia","volume":"73","author":"Wunderink","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.11.011_bib0043","article-title":"Comparative in vivo efficacies of tedizolid in neutropenic versus immunocompetent murine streptococcus pneumoniae lung infection models","volume":"61","author":"Abdelraouf","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.11.011_bib0044","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1128\/AAC.01303-12","article-title":"Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model","volume":"56","author":"Lepak","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524004521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524004521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T22:36:35Z","timestamp":1738881395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524004521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":44,"alternative-id":["S2213716524004521"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.11.011","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic\/pharmacodynamic analysis of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults by Monte Carlo simulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}